The latest selling price and medical insurance reimbursement details of osimertinib in 2024

Osimertinib (Osimertinib) is a targeted therapy for non-small cell lung cancer (NSCLC), especially for patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It inhibits tumor growth and spread by specifically inhibiting EGFR tyrosine kinase activity and blocking signal transduction of tumor cells. Since its launch, osimertinib has become an important treatment option for many NSCLC patients, significantly improving their quality of life and survival.

In In 2024, the selling price of osimertinib in my country will still remain at a high level, with a box of 80mg*30 tablets costing about five to six thousand yuan. However, for many patients, this price is still a significant burden. Fortunately, my country's medical insurance policy provides reimbursement support for eligible patients, greatly reducing their financial pressure. Patients who meet the reimbursement conditions can enjoy medical insurance reimbursement when purchasing osimertinib. The specific reimbursement ratio and limit may vary depending on regions and medical insurance policies.

In addition to original drugs, there are also some generic drugs on the market. These drugs are relatively low in price, providing patients with more choices. Among them, generic drugs produced by Lucius in Laos are very popular in the market. Its specifications are 80mg*30 tablets, which are sold for about 500 to 600 yuan, which is only about one-tenth of the price of the original drug. In addition, medicines of the same specification produced by Laos United Pharmaceuticals and Laos ASEAN Pharmaceuticals are also priced at about 600 to 700 yuan, which are also highly cost-effective. These generic drugs provide patients with more choices in terms of price, but when purchasing, patients should choose formal channels to ensure the quality and safety of the drugs.

It should be noted that because overseas drugs are affected by various factors such as exchange rates, their prices may change. Therefore, patients should promptly pay attention to market price dynamics when purchasing in order to make a more reasonable choice.

In general, osimertinib, as an important lung cancer treatment drug, will still maintain a high selling price in 2024. However, patients can reduce their financial burden to a certain extent through medical insurance reimbursement and the selection of generic drugs. At the same time, patients should also pay attention to market price dynamics when purchasing to ensure that they purchase cost-effective drugs.